Biotech deals show how to pluck without killing
Pharma mergers are usually a recipe for destroyed value. Yet big drugs companies need the innovation more prevalent at biotech firms. Sanofi’s increased stake in the $16 bln Regeneron, avoiding full control, is a good way to collect feathers without swallowing the bird.
This content is for Subscribers only
To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.